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3 
Translational Relevance  1 
The majority of cancer deaths result from ineffective treatment of metastatic disease. Currently, 2 
there is no satisfactory way to identify patients that are refractive to the standard of care. Positron 3 
emission tomography (PET) imaging offers a potential solution to this clinical problem through 4 
the noninvasive assessment of molecular processes that underpin acquired drug-resistance. The 5 
PET radiotracer (4S)-4-(3-[18F]fluoropropyl)-L-glutamate ([18F]FSPG) provides a surrogate 6 
marker of tumor antioxidant capacity through measurement of de novo glutathione biosynthesis. 7 
Elevated glutathione levels protect tumors from drug-induced oxidative stress, thereby conferring 8 
resistance. Here, we show that the magnitude of [18F]FSPG accumulation in tumors can be used to 9 
predict drug resistance and subsequently monitor treatment efficacy in animal models of ovarian 10 
cancer. Given that [18F]FSPG has already been used in pilot clinical trials, identification of drug 11 
resistance in patients may enable early intervention, potentially improving disease outcomes. 12 
  13 
 
4 
Abstract  1 
Purpose: Drug-resistance is a major obstacle for the effective treatment of patients with high grade 2 
serous ovarian cancer (HGSOC). Currently, there is no satisfactory way to identify HGSOC 3 
patients that are refractive to the standard of care. Here, we propose the system xc- radiotracer (4S)-4 
4-(3-[18F]fluoropropyl)-L-glutamate ([18F]FSPG) as a non-invasive method to measure 5 
upregulated antioxidant pathways present in drug resistant HGSOC.  6 
Experimental Design: Using matched chemotherapy sensitive and resistant ovarian cancer cell 7 
lines, we assessed their antioxidant capacity and its relation to [18F]FSPG uptake, both in cells and 8 
in animal models of human ovarian cancer. We identified the mechanisms driving differential 9 
[18F]FSPG cell accumulation and evaluated [18F]FSPG tumor uptake as predictive marker of 10 
treatment response in drug-resistant tumors.  11 
Results: High intracellular glutathione (GSH) and low reactive oxygen species corresponded to 12 
decreased [18F]FSPG cell accumulation in drug-resistant versus drug-sensitive cells. Decreased 13 
[18F]FSPG uptake in drug-resistant cells was a consequence of changes in intracellular cystine, a 14 
key precursor in GSH biosynthesis. In vivo, [18F]FSPG uptake was decreased ~80% in 15 
chemotherapy-resistant A2780 tumors compared to parental drug-sensitive tumors, with non-16 
responding tumors displaying high levels of oxidised-to-reduced GSH. Treatment of drug-resistant 17 
A2780 tumors with doxorubicin resulted in no detectable change in tumor volume, GSH or 18 
[18F]FSPG uptake.  19 
Conclusions: This study demonstrates the ability of [18F]FSPG to detect upregulated antioxidant 20 
pathways present in drug-resistant cancer. [18F]FSPG may therefore enable the identification of 21 
HGSOC patients that are refractory to standard-of-care, allowing the transferral of drug-resistant 22 
patients to alternative therapies, thereby improving outcomes in this disease. 23 
 
5 
Introduction  1 
High-grade serous ovarian cancer (HGSOC) is a devastating disease with a 5-year survival rate of 2 
less than 42% (1). Despite initial rates of response to platinum-based chemotherapy of over 80%, 3 
the median progression-free survival is just 18 months (2,3). Following first-line treatment, 4 
patients frequently relapse with platinum-sensitive disease. However, at each consequent relapse, 5 
the probability of response to further platinum-based treatment decreases (4), translating to a 6 
progressive decrease in effectiveness of platinum-based drugs. Clinically, response to platinum 7 
treatment in ovarian cancer patients is measured as the length of time from treatment to relapse, 8 
known as the platinum-free interval (PFI) (5). PFI, however, is a crude measure of drug sensitivity 9 
(6) and is particularly poor at predicting response for patients identified as ‘partially-sensitive’. 10 
These patients relapse 6-12 months after first line treatment and will all subsequently receive 11 
further platinum-based treatment, despite benefit only being appreciable in ~27-33% of cases (7). 12 
Better clinically-applicable biomarkers of platinum sensitivity in HGSOC are therefore urgently 13 
needed. The ability to identify patients refractive to the standard of care will enable the clinician 14 
to select the most appropriate second-line therapy for the individual patient, such as targeted-15 
therapy (e.g. PARP inhibitors), or biologics (e.g. bevacizumab). 16 
Biochemical antioxidant mechanisms play a critical role in development of acquired drug-17 
resistance in cancer (8). Antineoplastic agents have been shown to produce oxidative stress in 18 
patients who receive these drugs, resulting in cell death in tumors sensitive to treatment (9-17). 19 
The plasticity of tumors, however, enables phenotypic adaptation to these oxidizing therapies, 20 
frequently mediated through the upregulation of glutathione (GSH), the body’s most abundant 21 
antioxidant, in order to preserve cellular redox status and provide defense against reactive 22 
 
6 
oxygen species (ROS) that are produced under conditions of oxidative stress (18). Biopsy 1 
samples have shown GSH levels to increase up to 10-fold in ovarian tumors following 2 
development of resistance to alkylating agents compared to samples taken before treatment (19). 3 
Furthermore, modulators of GSH biosynthesis, such as buthionine sulfoximine (BSO), 4 
resensitize human ovarian tumors and cell lines to conventional therapy (20-23), highlighting 5 
the importance of GSH in the protection against tumor cell death. 6 
One of the key mediators of the cell’s antioxidant response is the amino acid transporter system 7 
xc-, which provides intracellular cysteine for de novo GSH biosynthesis. System xc- is a sodium 8 
independent transporter which under normal physiological conditions permits the exchange of one 9 
molecule of extracellular cystine, the dimeric form of cysteine, for one molecule of intracellular 10 
glutamate (24). Intracellularly, cystine is rapidly reduced to cysteine, which due to its low 11 
intracellular concentration (40–50 µM) is limiting for GSH synthesis (25). (4S)-4-(3-12 
[18F]fluoropropyl)-L-glutamate ([18F]FSPG) is a fluorine-18 labeled glutamate derivative that is 13 
specifically transported across the plasma membrane by system xc- (26), allowing the non-invasive 14 
assessment of system xc- transporter activity. Given the overexpression of system xc- in a wide-15 
range of tumor types, [18F]FSPG has been investigated clinically to produce high tumor-to-16 
background PET images in hepatocellular carcinoma (HCC), non-small cell lung cancer and 17 
intracranial malignancies (27-29). We have shown previously in preclinical models of HGSOC 18 
that [18F]FSPG uptake is sensitive to an elevation in GSH biosynthesis following drug-induced 19 
oxidative stress (30). Given the causal link between the levels of GSH and tumor resistance to 20 
therapy, here we examined [18F]FSPG uptake as a predictive marker of drug resistance in HGSOC 21 
prior to treatment and as a marker of response post-therapy.  22 
 
7 
Materials and methods  1 
Cell culture  2 
Parental wild-type (WT; 93112519), cisplatin-resistant (CisR; 93112517) and doxorubicin-3 
resistant (DoxR: 93112520) A2780 human ovarian cancer cells (Sigma Aldrich Ltd) were grown 4 
in RPMI 1640 media (ThermoFisher Scientific; 21875091) supplemented with 10% foetal bovine 5 
serum (ThermoFisher Scientific; 21875091) and 100 U.mL−1 penicillin, 100 µg.mL−1 streptomycin 6 
(Sigma Alrich Ltd: P4333). Patient derived PEO1, PEO4 and PEO6 human ovarian cancer cell 7 
lines (European Collection of Authenticated Cell Cultures; 10032308, 10032309 and 10032310 8 
were cultured as above, supplemented with 10 mM sodium pyruvate (Sigma; S8636). Cells were 9 
maintained at 37 °C and 5% CO2.  Clinically-formulated cisplatin (1 µM; TEVA UK Ltd; 10 
51642169) or liposomal doxorubicin (0.1 µM; Doxil; Janssen-Cilag Ltd; 668950) was added to 11 
the growth media of CisR and DoxR cells, respectively, every third passage. A2780 WT, CisR and 12 
DoxR were purchased from an authenticated cell bank and kept within 10 passages of the original 13 
vial. Short tandem repeat profiling could not be performed with PEO1, PEO4 or PEO6 cells. 14 
Mycoplasma testing was performed on a monthly basis.   15 
 16 
Drug sensitivity in cell culture 17 
Growth inhibition following drug treatment was characterized using the Vybrant® MTT Cell 18 
Proliferation Assay Kit (ThermoFisher Scientific, V13154), according to the manufacturer’s 19 
instructions. In 96-well plates, A2780 WT, CisR and DoxR cells (2,000 cells/well); and PEO1, 20 
PEO4 and PEO6 (5,000 cells/well) were treated with increasing concentrations of clinically-21 
formulated cisplatin or liposomal doxorubicin, 24 h post seeding (0.01 µM to 400 µM). Complete 22 
media containing no drug was used as a control. Absorbance was measured at λ = 570 nm using a 23 
 
8 
Multiskan FC Absorbance Plate Reader (THERMO-LABSYSTEMS). Viable cells were 1 
calculated as a percentage of the control group treated with no drug. Dose-response curves were 2 
generated and from them half-maximal growth inhibition (EC50) values were determined using 3 
GraphPad Prism (sigmoidal dose-response, fixed slope; v.6.0).  4 
 5 
Clonogenic assay 6 
PEO 1, PEO 4 and PEO 6 cells were seeded in 10 cm dishes at densities of 2 × 103, 2 × 103 and 1 7 
×104 cells in 10 mL media, respectively. 48 h post seeding, cells were treated with clinically-8 
formulated cisplatin (0.02 µM to 2 µM) for 72 h. At 72 h drug containing media was replaced with 9 
fresh growth media and colonies were left to grow for a further 7 days. Colonies were fixed and 10 
stained in 6.0% glutaraldehyde (Sigma, 340355) and 0.5% crystal violet (Sigma, C0775). Colonies 11 
which contained >50 cells were counted to determine the surviving fraction (SF) which was 12 
calculated by dividing the total number of colonies formed by the number of cells seeded, 13 
multiplied by the plating efficiency.  14 
 15 
Detection of intracellular oxidative stress 16 
ROS were detected in human ovarian cancer cell lines using the cell permeable fluorophore 17 
CellROX Orange (Invitrogen, C10443). A2780 WT, CisR and DoxR were seeded in 6-well plates 18 
at a density of 5 × 105 cells per well in 2 mL media 24 h prior to performing the assay. PEO 1, 19 
PEO 4 and PEO 6 cells were seeded at densities of 2 × 105, 6 × 105 and 8 × 105 cells per well (2 20 
mL media), respectively, 48 h prior to assay to ensure complete cell attachment. Fresh media 21 
supplemented with 2 mM glutamine was added to each 6-well plate one hour before the 22 
experiment. A final concentration of 1 µM CellROX Orange reagent was added to each well and 23 
 
9 
incubated for 30 min at 37 °C, protected from light. Cells were then washed with PBS, harvested 1 
using 0.05% trypsin-EDTA (Thermo Fisher Scientific; 25300062) and suspended in 1 mL of ice-2 
cold Hanks balanced salt solution (ThermoFisher Scientific; 14025092). The cell suspension was 3 
passed through a 35 µM filter and kept on ice prior to analysis on a LSRFortessa™ X-20 flow 4 
cytometer (561 nm laser and 586/15 bandpass filter; BD Biosciences), with 20,000 single cell 5 
events recorded per sample. Laser power remained constant between matched cell lines but was 6 
adjusted for A2780 vs. PEO lines.  Data were gated post-acquisition based on forward (FS) and 7 
side scattering (SS) profiles to include only single cell events and to exclude cellular debris. 8 
 9 
Glutamate quantification 10 
The glutamate concentration in cell lysates was determined using a glutamate colorimetric assay 11 
kit following the manufactures guidelines (Biovision; K629). Cells were seeded in 6-well plates 12 
for glutamate quantification at the densities described above. One hour prior to harvesting the cells, 13 
fresh media supplemented with 2 mM glutamine was added to all wells. Following harvesting with 14 
trypsin, cells were washed three times with 1 mL of ice-cold PBS. After the final wash, cells were 15 
suspended in 200 µL of glutamate assay buffer and sonicated using three sets of five, one-second 16 
pulses, on ice. Lysates were then centrifuged at 15,000 ´ g for 10 min at 4 °C and the supernatant 17 
taken for analysis. Total intracellular glutamate was normalized to protein concentration, 18 
determined using the Pierce BCA assay (ThermoFisher Scientific; 23225) according to the 19 
manufacturer’s instructions.   20 
 21 
Cystine measurements using liquid chromatography-mass spectrometry  22 
 
10 
Cells seeded in 6-well plates (specific densities stated above) were supplemented with fresh media 1 
containing 2 mM glutamine and 200 µM cystine for one hour. Briefly, following incubation, media 2 
samples were removed and diluted into 490 µL of ice-cold extraction solvent (v/v 50% methanol, 3 
30% acetonitrile and 20% deionized water). For intracellular cystine quantification, cells were 4 
subsequently washed three times with ice cold PBS and lysed in an appropriate volume of ice-cold 5 
extraction solvent to ensure ~3 ×106 cells/mL were collected. Both media samples and cell lysates 6 
were centrifuged at 15,000 ´ g at 1 °C for 10 min. The supernatants were subjected to liquid 7 
chromatography-mass spectrometry (LC-MS) as previously described (30).  8 
 9 
In vitro analysis of total GSH  10 
Cells were seeded into 6-well plates as described above. Total GSH was determined using either 11 
a colorimetric (Cayman Chemical; 703002) or luminescent (GSH/GSSG-Glo Assay kit, Promega; 12 
V6611) assay kit. For luminescent-based GSH quantification, cells were washed in ice-cold PBS, 13 
lysed in assay buffer and centrifuged at 15,000 ´ g at 4 °C for 10 min. 5 µL of supernatant along 14 
with 5 µL of GSH standards (1-100 µM) were added to white 96-well plates and total GSH 15 
determined according to manufacturer’s instructions. For colorimetric quantification, cells were 16 
processed as above, and total GSH detected according to the manufacturer’s guidelines. Total 17 
intracellular GSH was normalized to protein concentration. 18 
 19 
Western blot  20 
Western blot analysis was carried out using an established experimental method (31), adapted for 21 
use with the iBind Flex system (ThermoFisher Scientific) for primary and secondary antibody 22 
immunoblotting. For cell lysate collection, cells were seeded in 6-well plates, as described above. 23 
 
11 
Rabbit monoclonal antibodies against human xCT (Novus Biologicals; NB300-318), NRF2 (Cell 1 
Signaling Technology; 12721), GLS1 (Abcam; ab156876), GCL (Abcam; ab190685; 1:1000 2 
dilution), ABCC2 (Cell Signaling Technology; 12559), ABCC6 (Cell Signaling Technology; 3 
10666), ABCB1 (Cell Signaling Technology; 13342) and ABCG2 (Cell Signaling Technology; 4 
42078) were used for cell lysate analysis. Rabbit anti-human NRF2, GCL, p53 (Cell Signaling 5 
Technology; 2527), caspase3 Cell Signaling Technology; 9915) and cleaved-caspase3 antibodies 6 
(Cell Signaling Technology; 9915; 1:1000 dilution) were used for tumor lysate evaluation 7 
(prepared as described below). Actin was used as a loading control for all experiments (1:1000 8 
dilution; Cell Signaling Technology; 4967), with an HRP linked anti-rabbit IgG secondary 9 
antibody (1:2000 dilution; Cell Signaling Technology; 7074S). 10 
 11 
Radiotracer production  12 
Automated radiosynthesis of  [18F]FSPG was accomplished utilizing a Scintomics HBIII platform 13 
(Scintomics, Fürstenfeldbruck, Germany), according to a previously reported method (30). The 14 
decay corrected isolated radiochemical yield was 51 ± 3% (n = 6) after solid phase extraction 15 
purification, the radiochemical purity of [18F]FSPG was > 98% and the molar activity of the tracer 16 
was 4.2-21.9 GBq/µmol when starting from 2-4 GBq of [18F]fluoride. The total synthesis time, 17 
from [18F]fluoride in water to end of reformulation, was approximately 2 h. Clinical-grade 18 
[18F]FDG was obtained from PETNET solutions. 19 
 20 
Radiotracer uptake in cells 21 
Cells were seeded at the appropriate density in 6-well plates (see above). For all cell uptake 22 
experiments, radiotracers were added at a concentration of 0.185 MBq/mL. Cell uptake was 23 
 
12 
performed for 60 min at 37 °C in fresh growth media, following a previously established method 1 
(32). Radioactivity in samples was expressed as a percentage of the administered dose per mg 2 
protein.  3 
 4 
In vivo tumor models 5 
All animal experiments were performed in accordance with the United Kingdom Home Office 6 
Animal (scientific procedures) Act 1986. 5 × 106 A2780 WT and DoxR cancer cells in 100 µL 7 
Dulbecco’s PBS were injected subcutaneously into female Balb/c nu/nu mice aged 6-9 weeks 8 
(Charles River Laboratories). Tumor dimensions were measured using an electronic caliper and 9 
the volume calculated using the following equation: volume = ((π/6) × h × w × l), where h, w and 10 
l represent, height, width and length, respectively. Tumor size was monitored daily and imaging 11 
studies took place when tumor volume reached ~100 mm3.  12 
 13 
MicroPET imaging studies 14 
Static PET scans were acquired on a Mediso NanoScan PET/CT system (1-5 coincidence mode; 15 
3D reconstruction; CT attenuation-corrected; scatter corrected). Mice received a bolus intravenous 16 
injection of approximately 3.7 MBq of [18F]FSPG through a tail vein cannula. Following a 40 min 17 
uptake period, a 20 min PET scan was acquired. Animals were maintained under isofluorane 18 
anesthesia (1.5-2 % in oxygen) at 37 °C during radiotracer administration and throughout the scan. 19 
CT images were acquired for anatomical visualization (480 projections; helical acquisition; 50 20 
kVp; 300 ms exposure time). Following image reconstruction, (Tera-Tomo 3D; 4 iterations, 6 21 
subsets; 0.4 mm isotropic voxel size), VivoQuant software (Invicro) was used to quantify 22 
radiotracer uptake. Tumor and hindlimb muscle volumes of interest were constructed from 2D 23 
 
13 
regions drawn manually using the CT image as reference. Data were expressed as percent injected 1 
dose per milliliter of tissue (%ID/mL). Tumor-to-background ratios were calculated by dividing 2 
the tumor %ID/mL by the muscle %ID/mL. 3 
 4 
In vivo Doxil treatment studies  5 
For treatment response studies, mice bearing ~100 mm3 size-matched A2780 DoxR tumors were 6 
treated by intraperitoneal (i.p.) injection with Doxil (10 mg/kg). A cohort of untreated mice bearing 7 
100 mm3 A2780 DoxR tumors were imaged as pre-treatment controls. 24 h post injection (D1), 8 
Doxil-treated mice were imaged with [18F]FSPG PET as described above. A second cohort of mice 9 
received a further two Doxil doses, 2 and 5 days after the initial dose. These mice were 10 
subsequently imaged with [18F]FSPG PET 6 days following the initial Doxil treatment (D6).   11 
 12 
Ex vivo tumor sample preparation  13 
Immediately following sacrifice, tumor tissue was dissected, snap frozen in liquid nitrogen and 14 
stored at -80 °C.  For GSH and GSSG analysis, each tumor sample was split into two pieces, placed 15 
into lysis Matrix tubes containing 1.4 mm ceramic beads (MP Biomedicals; 116913050) and assay 16 
buffer (GSH/GSSG-Glo assay, Promega) with or without N-ethyl maleimide (NEM; 1 mM), 17 
respectively. For Western blot samples, tumor tissue was added to separate Matrix tubes containing 18 
1.4 mm ceramic beads and RIPA buffer. Tumor samples were lysed by rapid shaking using a high-19 
speed benchtop reciprocating homogenizer (Fastprep-24™ Sample Preparation Instrument, MP 20 
Biomedicals). The lysates were centrifuged at 15,000 ´ g at 4 °C for 10 min and the supernatant 21 
collected for analysis. For all ex vivo experiments, data were expressed per mg of protein. 22 
 23 
 
14 
Statistics 1 
All data were expressed as the mean ± one standard deviation (SD). Statistical significance was 2 
determined using analysis of variance (ANOVA) followed by t-tests multiple comparison 3 
correction (Tukey method; GraphPad Prism v.6.0).  4 
 5 
 6 
Results  7 
Cell model characterization  8 
To investigate the role of intracellular redox homeostasis on tumor response to treatment, we used 9 
two sets of matched human ovarian cell lines with varying levels of drug sensitivity. The A2780, 10 
CisR and DoxR lines were established previously from chronic exposure of the drug-sensitive 11 
A2780 WT cells to increasing concentrations of either cisplatin or doxorubicin, respectively 12 
(33,34). The cisplatin-sensitive PEO1 cell line was cultured from a patient with relapsed ovarian 13 
cancer 22 months after 5-fluorouracil and chlorambucil combination chemotherapy with cisplatin. 14 
The PEO4 cisplatin resistant cell line was cultured from ascites taken from the same patient ten 15 
months later after further progressive disease but prior to re-treatment with high dose cisplatin. 16 
Finally, the PEO6 cell line was obtained from ascites a further three months later, after the patient 17 
failed to respond to high-dose cisplatin (35).  18 
 19 
We initially verified drug response rates of the matched A2780 cell lines in culture. CisR cells 20 
displayed moderate sensitivity to cisplatin in comparison to WT cells, with an EC50 of 10.1 µM ± 21 
0.3 µM versus 0.8 µM ± 0.2 µM, respectively (n = 3; P < 0.0001; Fig. 1A), confirming previously-22 
reported values (36). DoxR cells were resistant to prolonged exposure at high micromolar 23 
 
15 
doxorubicin concentrations (EC50 = 29 µM ± 2.1 µM and 0.47 µM ± 0.03 µM for DoxR and WT, 1 
respectively; n = 3; P < 0.0001; Fig. 1B), again confirming previous findings (36). Interestingly, 2 
CisR and DoxR cells were cross-resistant to doxorubicin and cisplatin, respectively, despite not 3 
having been exposed to these drugs – possibly highlighting a shared mechanism of resistance. The 4 
EC50 for cisplatin in PEO1 cells was 2.6 µM ± 0.85 µM, with PEO4 cells exhibiting lowered 5 
sensitivity to cisplatin in comparison to PEO1 cells, with an EC50 value of 14 µM ± 5.3 µM (n = 6 
3; P = 0.01; Fig 1C). There was no significant difference in EC50 between PEO1 and PEO6 cells 7 
(n = 3; P = 0.083).  However, the dose required to kill 90% of the cells was 3-fold higher for PEO6 8 
(19 µM ± 4.8 µM for PEO1 vs. 66 µM ± 35 µM for PEO6; n = 3; P = 0.04), revealing a small 9 
subset of PEO6 cells to be highly resistant. Motivated by this, a clonogenic assay was used to 10 
further explore cisplatin resistance in these cell lines. PEO6 cell lines showed decreased sensitivity 11 
to 0.5 µM cisplatin following treatment compared to PEO1 cells (SF = 0.78 ± 0.22 vs. 0.432 ± 12 
0.02, P = 0.04, n = 3), with both PEO4 and PEO6 cell lines exhibiting improved survival following 13 
treatment with 2 µM cisplatin (SF = 0.08 ± 0.04, 0.12 ± 0.04 and 0.005 ± 0.004 for PEO4, PEO6 14 
and PEO1, respectively; n = 3; P = 0.05, PEO1 vs PEO4; P = 0.008, PEO1 vs. PEO 6; 15 
Supplemental Fig. S1). 16 
 17 
Drug-resistant ovarian cancer cells upregulate antioxidant defense mechanisms  18 
We hypothesized that drug resistance in these cell lines was mediated, at least in-part, by the 19 
upregulation of key antioxidant pathways. In support of this hypothesis, we found that basal 20 
intracellular ROS levels were decreased 24% in CisR (P = 0.03) and 86% in DoxR cells (P < 21 
0.0001), compared to the WT parental cells (n = 3; Fig. 1D). Intracellular ROS in the PEO4 and 22 
PEO6 cell lines were also decreased 60% (P = 0.02) and 55% (P = 0.03), respectively, compared 23 
 
16 
to PEO1 (n = 4; Fig. 1E).  Accompanying this decrease in intracellular ROS, intracellular GSH 1 
was increased 1.8-fold in the CisR cells and 3.3-fold in DoxR cells, compared to WT cells (n = 3; 2 
P = 0.04, WT vs. CisR; and 0.0002, WT vs. DoxR; Fig. 1F), with GSH increased 2.7- and 3.8-fold 3 
in the PEO4 and PEO6 cells compared to PEO1 (n = 3; P < 0.0001, PEO1 vs. PEO4; and P < 4 
0.0001, PEO1 vs. PEO6; Fig. 1G). 5 
 6 
[18F]FSPG, but not [18F]FDG uptake predicts drug sensitivity in A2780 cells 7 
We have previously shown that system xc- provides a functional readout of de novo GSH 8 
biosynthetic flux, which can be imaged non-invasively using [18F]FSPG PET (30). Given that the 9 
rate of GSH biosynthesis may provide a surrogate marker of drug sensitivity, we next assessed 10 
system xc--mediated [18F]FSPG uptake in drug-sensitive and drug-resistant ovarian tumor cells in 11 
culture. The molecular structure of [18F]FSPG is shown in Fig 2A. In CisR cells, [18F]FSPG 12 
accumulation was reduced by 57% compared to WT, falling from 9.9 ± 1.1 % radioactivity/mg 13 
protein to 4.3 ± 0.3 % radioactivity/mg protein (P < 0.0001). In the more resistant DoxR cells, 14 
[18F]FSPG accumulation was 81% lower than WT (1.6 ± 0.1 % radioactivity/mg protein; n = 4; P 15 
< 0.0001; Fig. 2B). [18F]FDG is routinely used in the clinic for cancer diagnosis and staging. In 16 
contrast to [18F]FSPG, there was no correlation between [18F]FDG uptake and the magnitude of 17 
drug resistance (Supplemental Fig. S2), with [18F]FDG cell uptake measured at 1.5 ± 0.2 % 18 
radioactivity/mg protein, 10.6 ± 2.1 % radioactivity/mg protein and 6.3 ± 1.1 % radioactivity/mg 19 
protein, for CisR, DoxR and WT, respectively (n = 3). Confirming findings in the A2780 cell lines, 20 
[18F]FSPG uptake was decreased 29 % and 41 % in the more resistant PEO4 and PEO6 cell lines, 21 
compared to PEO1 cells (2.5 ± 0.3 % radioactivity/mg protein, 1.8 ± 0.2 % radioactivity/mg protein 22 
 
17 
and 1.5 ± 0.3 % radioactivity/mg protein, for PEO1, PEO4 and PEO6, respectively; (n = 3-4; P = 1 
0.03, PEO1 vs PEO4; and P = 0.003, PEO1 vs PEO6; Fig. 2C).  2 
 3 
Intracellular cystine is decreased  in chemotherapy resistant cells 4 
System xc- is the key transporter used in tumor cells for the exchange of intracellular glutamate 5 
with extracellular cystine (Fig. 3A). The altered radiotracer flux through system xc- occurred in the 6 
absence of any changes in xCT protein expression, the transporter component of system xc-. Splice 7 
variants of glutaminase 1, the kidney-type glutaminase (KGA) isoform and the glutaminase C 8 
isoform (GAC), which provide intracellular glutamate through glutaminolysis, showed elevated 9 
expression in the CisR and DoxR resistant lines in comparison to WT (Fig. 3B). The PEO4 and 10 
PEO6 cell lines showed increased expression of the redox-sensitive transcription factor NRF2 and 11 
one of its downstream targets glutamate-cysteine ligase (GCL) – the rate limiting enzyme in GSH 12 
biosynthesis (Fig. 3B).  13 
The absence of changes in [18F]FSPG transporter expression motivated us to investigate the roles 14 
of intracellular concentrations of glutamate and cystine to determine their potential role in 15 
[18F]FSPG retention. In the A2780 cell lines, there was no significant difference in the intracellular 16 
concentration of glutamate, despite the observed differences in glutaminase expression (n = 3; P 17 
> 0.05; Fig. 3C). Intracellular cystine however was decreased over 90% in the drug resistant 18 
A2780 lines, compared to drug-sensitive (n = 3; P = 0.0019, WT vs. CisR; and P = 0.0021, WT 19 
vs. DoxR); Fig. 3F). Markedly lower intracellular cystine was also measured in PEO4 and PEO6 20 
cells compared to PEO1s (86% and 65% decrease, respectively; n = 3; P = 0.018, PEO1 vs. PEO4; 21 
and P = 0.059, PEO1 vs. PEO6; Fig. 3F). Additionally, in the PEO cell lines, there was a 54% 22 
 
18 
decrease in intracellular glutamate for PEO4 cells and 40% in the PEO6 cells, compared to PEO1 1 
(n = 3; P = 0.005, PEO1 vs. PEO4; and P = 0.02, PEO1 vs. PEO6; Fig. 3D). 2 
 3 
ABC transporter expression 4 
ATP-binding cassette (ABC) transporter proteins play an important role in acquired drug 5 
resistance, facilitating the efflux of anticancer drugs, frequently as GSH-conjugates (37). To 6 
explore the role of key ABC transporters and their potential link to the tumor antioxidant response, 7 
we examined their expression in our panel of ovarian cancer cells. In the DoxR cells, ABCB1 and 8 
ABCC2 was expressed to high levels, whereas functional expression of these transporters was 9 
absent in the WT and CisR lines. Conversely, ABCG2 expression was elevated in WT cells, with 10 
no expression observed in all other lines. The ABCC6 transporter was not expressed in any of the 11 
cell lines tested, with PEO1, PEO4 and PEO6 cells expressing neither ABCB1, ABCC2, ABCG2 12 
nor ABCC6 (Supplemental Fig. S3). 13 
 14 
[18F]FSPG uptake can differentiate chemotherapy sensitive and resistant tumors in vivo 15 
We next evaluated the specificity of [18F]FSPG to non-invasively detect drug resistance in living 16 
subjects using small animal PET. [18F]FSPG distribution was characterized by high uptake in WT 17 
tumors 40-60 min post injection. Conversely, low tumor-associated radioactivity was measured in 18 
size-matched DoxR tumors. Representative static [18F]FSPG maximum-intensity projections 19 
(MIPs) are shown in Fig. 4A, with single-slice images are displayed in Supplementary Fig. S4, 20 
and the corresponding three-dimensional (3D) movies displayed as movies S1 and S2. 21 
Quantification of image-derived [18F]FSPG uptake revealed a 79% decrease in [18F]FSPG uptake 22 
in DoxR tumors compared to WT tumors (7.9 ± 0.7 %ID/mL vs. 1.7 ± 0.4 %ID/mL; n = 5-6 23 
 
19 
animals/group; P < 0.0001; Fig. 4B). [18F]FSPG tumor retention was above background tissue 1 
uptake for both drug sensitive and drug resistant tumors, with tumor-to-muscle ratios of 18.8 ± 5.2 2 
and 2.7 ± 1.6 for WT and DoxR, respectively (n = 5-6 animals/group; P < 0.0001; Supplementary 3 
Fig. S5). To understand redox alterations that may underpin this differential [18F]FSPG uptake, 4 
the levels of GSH and GSSG were evaluated in snap-frozen tumor samples. In DoxR tumors, GSH 5 
was increased 1.6-fold compared to WT, with a ~20-fold increase in the ratio of GSSG to GSH 6 
measured in the drug-resistant tumors (n = 3; P = 0.0002; Fig. 4C). Western blot analysis revealed 7 
xCT, NRF2, GCLC and glutaminase protein expression remained unchanged between the sensitive 8 
and resistant tumors. However, a stabilization in p53 expression was observed in the DoxR tumor 9 
samples (Fig. 4D). PEO1, PEO4 and PEO6 cells failed to grow in vivo, meaning that we were 10 
unable to further corroborate our findings in cell culture using this model. 11 
 12 
[18F]FSPG uptake is unchanged in DoxR tumors following therapy  13 
We have shown previously that [18F]FSPG is an early and sensitive marker of drug-induced 14 
oxidative stress in A2780 WT tumors (30). To further explore [18F]FSPG as a robust marker of 15 
both drug response and treatment failure, we assessed [18F]FSPG uptake in DoxR tumor xenografts 16 
over the same 6-day Doxil treatment time course (Fig. 5A). Representative [18F]FSPG MIPs are 17 
shown in Fig. 5B, with single-slice images illustrated in Supplementary Fig. S6, and 18 
corresponding 3D movies displayed as movies S3, S4 and S5.  Unlike in the A2780 WT tumors 19 
(30), there was no significant difference in [18F]FSPG tumor uptake between animals imaged on 20 
D0, D1 and D6 (1.8 ± 0.4 %ID/mL, 1.9 ± 0.4 %ID/mL and 1.7 ± 0.6 %ID/mL, respectively; n = 21 
5-6 animals/group; P = 0.94, D0 vs. D1; and P = 0.9, D0 vs. D6; Fig. 5C). Over the course of the 22 
experiment, there was also no significant difference in tumor size measured between treated and 23 
 
20 
untreated animals (Fig. 5D), indicating failure of this treatment regimen. Supporting these 1 
findings, there was no change in tumor GSH, GSSG:GSH ratio (Fig. 5E and F), markers of 2 
oxidative stress (NRF2) or levels of apoptosis following treatment, shown through measurements 3 
of caspase 3 cleavage (Fig. 5G). 4 
 5 
 6 
Discussion  7 
Chemotherapy agents are extensively used for the treatment of many cancers, with the aim to target 8 
rapidly-growing tissue, often through DNA damage, growth arrest and the induction of cell death 9 
(38). The low therapeutic index of antineoplastic drugs, however, means that relatively small 10 
changes in the sensitivity of tumor cells to these agents can be detrimental to patient outcome. The 11 
development of novel imaging methods to monitor drug-induced cell death as an indicator of drug 12 
efficacy have shown great promise, potentially allowing for a timely intervention following the 13 
emergence of drug resistance (39-43). Monitoring response post-treatment, however, is often 14 
hampered by difficulties predicting the timescale of response in individual patients. Furthermore, 15 
the effective clearance of dying tumor cells by the innate immune system and the high cell turnover 16 
in untreated tumors results in cell death being a temporally unstable biomarker of response (44).  17 
 18 
The adaptations that occur in cancer cells as a consequence of acquired drug resistance provide 19 
ample opportunity for the development of novel, targeted PET radiotracers that have the potential 20 
to predict response prior to therapy. Here, we used the redox-sensitive radiotracer, [18F]FSPG, as 21 
a surrogate marker of drug resistance. Drug resistant cancer cells have the ability to maintain a 22 
highly reduced intracellular environment to protect themselves from the harmful effects of 23 
 
21 
oxidative stress, thereby conferring treatment resistance (45-47). Using matched drug-sensitive 1 
and drug-resistant ovarian cancer cells, we showed that resistance to either cisplatin or doxorubicin 2 
corresponded with an increase in tumor antioxidant capacity, defined through the elevation of 3 
intracellular GSH and a decrease in ROS. A key component of the tumor’s antioxidant system is 4 
system xc-, which provides cystine for de novo GSH biosynthesis.  Differential xc- activity in drug-5 
resistant versus sensitive A2780 and PEO cells was quantified through measurements of 6 
[18F]FSPG cell accumulation, which occurred in the absence of changes in transporter expression. 7 
In drug-sensitive cells, [18F]FSPG accumulated to high levels, whereas low intracellular levels 8 
were observed in cells resistant to therapy. In comparison, baseline glucose utilization, shown 9 
through [18F]FDG uptake, was a poor predictive marker of response.  10 
 11 
We have previously shown that the intracellular concentrations of system xc- substrates glutamate 12 
and cystine mediate [18F]FSPG uptake and retention in A2780 WT tumors (30). In addition, drug-13 
induced oxidative stress in these tumor cells resulted in rapid depletion of intracellular cystine as 14 
a consequence of an increase in the rate of de novo GSH biosynthesis, which could be imaged by 15 
[18F]FSPG PET (30). In all drug-resistant cell lines examined here, intracellular cystine 16 
concentrations were substantially decreased compared to drug-sensitive lines, corresponding to 17 
large increases in steady-state GSH. In the drug-resistant PEO4 and PEO6 cell lines, where 18 
intracellular GSH concentrations were highest of all the cell lines examined, intracellular 19 
glutamate – another biosynthetic precursor of GSH – was also significantly decreased compared 20 
to the drug-sensitive PEO1 cells. Lowered intracellular glutamate was not observed in the drug-21 
resistant A2780 cell lines which expressed elevated levels of GLS1, a key metabolic enzyme that 22 
catalyzes the conversion of glutamine to glutamate. Through increased glutaminolysis, it is thought 23 
 
22 
that drug-resistant A2780 cells maintained high intracellular glutamate concentrations despite 1 
elevated flux into GSH. Conversely, this compensatory mechanism was absent in the resistant 2 
PEO4 and PEO6 cell lines which did not upregulate GLS1, which may account for the reduction 3 
in intracellular glutamate when compared to PEO1 cells.  The PEO4 and PEO6 cell lines did 4 
however upregulate the expression of the redox-sensitive transcription factor NRF2 which 5 
paralleled elevated GCL, its downstream target and the rate limiting enzyme in GSH biosynthesis. 6 
These data suggest there are multiple mechanisms at play that result in elevated de novo GSH 7 
biosynthesis and consequent cystine consumption in drug-resistant cells.  8 
 9 
Low levels of intracellular cystine present in drug-resistant cells accompanied decreased 10 
[18F]FSPG retention compared to their parental drug-sensitive cell line. This decrease in [18F]FSPG 11 
accumulation can be understood by considering the mechanism of system xc- transport. System xc- 12 
activity is mediated by the membrane concentration gradients of both glutamate (high intracellular, 13 
low extracellular) and cystine (low intracellular, high extracellular) (48). Depletion of intracellular 14 
cystine acts to increase system xc--mediated cystine uptake into the cell, with a corresponding 15 
increase in glutamate efflux. As [18F]FSPG can replace glutamate as an exchange partner with 16 
cystine, lowered intracellular [18F]FSPG measured in drug resistant tumors may be a consequence 17 
of elevated radiotracer efflux from the cell. Additionally, increased cystine uptake may 18 
alternatively lead to higher occupancy of the transporter by the natural substrate and therefore 19 
lower [18F]FSPG uptake. Furthermore, a decrease in intracellular glutamate, as observed in PEO4 20 
and PEO6 cells, will lower the rate of glutamate efflux, thereby reducing the rate of both cystine 21 
and [18F]FSPG uptake. Taken together, a depletion of either intracellular glutamate or cystine is 22 
predicted to reduce overall [18F]FSPG accumulation, as shown in this study. A schematic 23 
 
23 
illustrating the putative relationship between the intracellular-to-extracellular concentration 1 
gradients of cystine and glutamate, [18F]FSPG tumor retention, and drug resistance is shown in 2 
Fig. 6.  3 
 4 
Corroborating our findings in culture, tumor-associated [18F]FSPG was decreased in drug-resistant 5 
A2780 DoxR xenografts when compared to drug-sensitive WT tumors, which was also 6 
independent of any changes in xCT expression. In the drug-resistant DoxR tumors, we observed 7 
an elevation in total tumor GSH and 21-fold increase in GSSG:GSH ratio when compared to WT 8 
– indicating an adaptive mechanism to maintain a decreased intracellular environment through 9 
upregulation of this key antioxidant pathway. This reducing environment facilitates the protection 10 
against ROS-induced cell death, subsequently lowering drug induced toxicity and resulting in 11 
drug-resistance. We have previously shown that [18F]FSPG uptake is an early and sensitive marker 12 
of treatment response in doxorubicin-sensitive A2780 WT tumors (30). WT tumors were treated 13 
with Doxil over the same 6 day treatment time course described here (Fig. 5A), with [18F]FSPG 14 
retention decreased by a significant 42% 24h post therapy. In these drug-sensitive WT tumors a 15 
reduction in [18F]FSPG coincided with a depletion in tumor GSH but occurred prior to measurable 16 
changes in tumor volume, which became evident 4 days after the initial round of treatment (30). 17 
Given that DoxR tumors upregulate the antioxidant GSH and maintain low levels of ROS, we 18 
asked if this reducing environment was sufficient to protect these tumors from oxidizing Doxil 19 
treatment and whether [18F]FSPG PET could monitor drug response (or its absence) post therapy. 20 
In these resistant tumors, three doses of Doxil therapy over the 6-day treatment time course did 21 
not induce caspase 3 activation, with treatment unable to alter tumor growth in vivo. Treatment 22 
failure corresponded with an absence of changes in total GSH and the GSSG:GSH ratio from 23 
 
24 
baseline. Importantly, no differences in [18F]FSPG tumor uptake were measured between treatment 1 
groups, indicating that [18F]FSPG uptake can not only be used to predict drug resistance, but 2 
monitor treatment response, and indeed treatment failure.   3 
 4 
The non-invasive imaging of chemotherapy-resistant xenografts with [18F]FSPG holds some 5 
limitations. The tumoral heterogeneity in human ovarian cancer results in multiple highly complex 6 
mechanisms of chemotherapy resistance, as previously reported (49,50).  We have shown here that 7 
[18F]FSPG can be used as a non-invasive method to identify chemotherapy-resistance tumors 8 
through measurement of their antioxidant capacity. Other well-established mechanisms of 9 
resistance include the upregulation of the ABC efflux pumps (37). In the cell lines tested here, 10 
there was no clear pattern of ABC transporter upregulation in the drug-resistant cells, with only 11 
A2780 DoxR cells expressing detectable levels of ABCB1 and ABCC2. In DoxR cells, elevated 12 
GSH observed (Fig. 1F) may be a requirement for ABC transporter-mediated efflux of 13 
doxorubicin-GSH conjugates. Upregulation of de novo GSH synthesis as a consequence of ABC 14 
transporter expression could presumably affect intracellular cystine levels and therefore reduce 15 
[18F]FSPG retention. From this current study, however, it is unclear whether the detection of 16 
resistant tumors using mechanisms to overcome insult with chemotherapeutic drugs that do not 17 
cause changes in the cellular antioxidant response will cause a change in tumor [18F]FSPG uptake. 18 
Moreover, it is expected that metabolic adaptation in tumors, such as altered anaplerotic flux, may 19 
alter [18F]FSPG uptake irrespective of the resistance-status of the cells. Regarding clinical utility, 20 
it may therefore be necessary to acquire a baseline scan for each patient upon diagnosis, with 21 
follow-up [18F]FSPG scans performed upon relapse. Importantly, however, as [18F]FSPG has 22 
 
25 
already been examined in human clinical trials, there are few barriers to the use of [18F]FSPG as a 1 
predictive marker of drug resistance in patients. 2 
 3 
Conclusion  4 
Here, we have shown that [18F]FSPG uptake is uniquely sensitive to the upregulated antioxidant 5 
pathways present in drug-resistant human ovarian tumors. In the drug-resistant lines, low 6 
[18F]FSPG uptake corresponded with decreased ROS and higher baseline GSH concentrations in 7 
comparison to drug-sensitive tumors. [18F]FSPG may therefore enable the identification of ovarian 8 
cancer patients that are refractory to the standard of care, as well as monitor their response post-9 
treatment. Transferal of drug-resistant patients to alternative therapies has the potential to increase 10 
tumor response and patient survival. In addition, [18F]FSPG PET holds great potential for the 11 
prediction of drug sensitivity in a range of other malignancies that share the same underlying 12 
mechanisms of resistance. 13 
 14 
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Figure Legends 1 
Fig. 1. Chemotherapy resistance accompanies protection against oxidative stress in human 2 
ovarian cell lines. Sensitivity of A2780 (A and B) and PEO cell lines (C) to treatment with 3 
cisplatin (A and C) or Doxil (B), as measured by an MTT assay.  Data is expressed as a percentage 4 
response compared to untreated cells following 72 h treatment (n = 3). (D and E) Global levels of 5 
intracellular ROS in A2780 (D) and PEO (E) ovarian cancer cell lines, measured by flow 6 
cytometry. Different laser power was used for data acquisition of A2780 matched lines vs PEO. 7 
(F and G) Intracellular baseline GSH levels in the drug sensitive and drug resistance A2780 (F) 8 
and PEO cell lines (G). Scatter plots represent individual biological repeats. *, P < 0.05; **, P < 9 
0.01; ***, P < 0.001. 10 
 11 
Fig 2. [18F]FSPG uptake is decreased in drug-resistant cells. (A) Molecular structure of 12 
[18F]FSPG. (B and C) [18F]FSPG cell uptake and accumulation following 60 min incubation in 13 
A2780 cell lines (B) and PEO cell lines (C). Scatter plots represent biological repeats performed 14 
in triplicate. *, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P < 0.0001. 15 
 16 
Fig. 3. Intracellular levels of cystine are decreased in drug-resistant cancer cells. (A) Model 17 
of [18F]FSPG accumulation, with mechanisms known to control radiotracer accumulation. Uptake 18 
of [18F]FSPG is predicted to occur through exchange with intracellular glutamate, with efflux 19 
controlled by the exchange with extracellular cystine. Red and green triangles represent the 20 
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concentration gradients of cystine and glutamate across the plasma membrane. e, extracellular; i, 1 
intracellular. (B) Western blot analysis of the levels of xCT, glutaminase isozymes (kidney-type 2 
glutaminase (KGA) and glutaminase-C (GAC)), glutamate-cysteine ligase (GCL) and NRF2. 3 
Intracellular levels of glutamate (C and D) and cystine (E and F) in A2780 (C and E) and PEO 4 
human ovarian cancer cell lines (D and F). Data presented as mean with individual scatter plots 5 
representing independent experiments. *, P < 0.05; **, P < 0.01.   6 
 7 
Fig. 4. [18F]FSPG uptake is decreased in Doxil-resistant A2780 tumors (A) Representative 8 
PET/CT maximum intensity projections in WT and DoxR tumor-bearing mice 40-60 min post-9 
injection. White arrowheads indicate the tumor margins. (B) Quantification of [18F]FSPG tumor 10 
uptake. Total GSH (C) and the ratio of GSSG:GSH (D) in ex vivo tumor samples. ***, P < 0.001. 11 
Scatter plots represent tumors from separate mice. (D) Western blot analysis evaluating the 12 
expression of proteins involved in cellular antioxidant response and proteins that may influence 13 
[18F]FSPG uptake (n = 3 xenografts per tumor cell line). Actin was used as a loading control. KGA, 14 
kidney-type glutaminase; GAC, glutaminase-C; GCL, glutamate-cysteine ligase.   15 
 16 
Fig. 5. [18F]FSPG uptake is unchanged in A2780 DoxR tumors that fail to respond to therapy. 17 
(A) The treatment and imaging protocol. (B) Representative PET/CT maximum intensity 18 
projections in chemotherapy resistant A2780 DoxR tumor-bearing mice prior to treatment (D0) or 19 
following either 24 h (D1) or 6 days of Doxil treatment (D6). SG, salivary glands. (C) 20 
Quantification of tumor uptake in all three treatment groups (p > 0.05). (D) A2780 DoxR tumor 21 
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growth curves in untreated and drug-treated mice (p > 0.05). Total intracellular GSH concentration 1 
(E) and GSSG:GSH ratio (F) from tumor samples taken from untreated and Doxil-treated mice 2 
taken immediately following PET imaging (p > 0.05). Scatter plots represent tumors from separate 3 
mice. (G) Expression of apoptotic cell death and oxidative stress protein markers. Actin was used 4 
as a loading control. Prolonged exposure relates to a 45 min exposure using a cleaved caspase 3 5 
primary antibody.  6 
 7 
Fig. 6.  Schematic illustrating the proposed mechanism of [18F]FSPG accumulation in 8 
sensitive and drug-resistant tumors. Changes in the concentration gradients of either cystine or 9 
glutamate in drug resistant (A) and drug sensitive (B) tumor cells are predicted to cause alterations 10 
in [18F]FSPG tumor retention. A decrease in intracellular cystine leads to an increase in the 11 
concentration gradient across the membrane, expected to result in increased efflux of [18F]FSPG 12 
in exchange for more extracellular cystine. Alternatively, decreased uptake in drug-resistant 13 
tumors may be a consequence of increased competition between cystine and [18F]FSPG at the site 14 
of the transporter (denoted by the yellow star). Red and green triangles represent the concentration 15 
gradients of cystine and glutamate, respectively. e, extracellular; i, intracellular.  16 
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